Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

Targeted Oncology

Volumn 10, Issue 1, 2015, Pages 111-123

  Brana, Irene ^a   Calles, Antonio ^b,c   LoRusso, Patricia M ^d   Yee, Lorrin K ^e,f   Puchalski, Thomas A ^g   Seetharam, Shobha ^g   Zhong, Bob ^g   de Boer, Carla J ^h   Tabernero, Josep ^a   Calvo, Emiliano ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b START   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

^d WAYNE STATE UNIVERSITY   (United States)

^e Northwest Medical Specialties   (United States)

^f Vista Oncology   (United States)

^g JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^h Janssen Biologics   (Netherlands)

Author keywords

Carlumab; Chemokine CCL2; Clinical trial; Combination chemotherapy; Phase 1; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARLUMAB; DEOXYCYTIDINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PACLITAXEL; TAXOID;

ADULT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASMS; PHASE 1 CLINICAL TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; TAXOIDS;

EID: 84939873437     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-014-0320-2     Document Type: Article

References (31)

1. Guilloton F, Caron G, Ménard C, Pangault C, Amé-Thomas P, Dulong J, De Vos J, Rossille D, Henry C, Lamy T, Fouquet O, Fest T, Tarte K (2012) Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119:2556–2567. doi:10.1182/blood-2011-08-370908
2. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 91:3652–3656
3. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB (2005) CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 166:675–684. doi:10.1016/S0002-9440(10)62289-4
4. Kokubo S, Sakai N, Furuichi K, Toyama T, Kitajima S, Okumura T, Matsushima K, Kaneko S, Wada T (2012) Activation of p38 mitogen-activated protein kinase promotes peritoneal fibrosis by regulating fibrocytes. Perit Dial Int 32:10–19. doi:10.3747/pdi.2010.00200
5. Tang C-H, Tsai C-C (2012) CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. Biochem Pharmacol 83:335–344. doi:10.1016/j.bcp.2011.11.013
6. Allavena P, Bianchi G, Giardina P, Polentarutti N, Zhou D, Introna M, Sozzani S, Mantovani A (1996) Migratory response of human NK cells to monocyte-chemotactic proteins. Methods 10:145-149. doi:10.1006/meth.1996.0088
7. Ksiazkiewicz M, Gottfried E, Kreutz M, Mack M, Hofstaedter F, Kunz-Schughart LA (2010) Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts. Immunobiology 215:737–747. doi:10.1016/j.imbio.2010.05.019
8. Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180:2011–2017. doi:10.4049/jimmunol.180.4.2011
9. Linde N, Gutschalk CM, Hoffmann C, Yilmaz D, Mueller MM (2012) Integrating macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages. PLoS ONE 7:e40058. doi:10.1371/journal.pone.0040058
10. Hao N-B, Lü M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M (2012) Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012:1–11. doi:10.1155/2012/948098
11. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M (2001) Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92:1085–1091. doi:10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K
12. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6:3282–3289
13. Sun T, Lee G-SM, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, Kantoff PW (2011) Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res 17:1546–1552. doi:10.1158/1078-0432.CCR-10-2015
14. Deng W, Gu X, Lu Y, Gu C, Zheng Y, Zhang Z, Chen L, Yao Z, Li L-Y (2012) Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization. Angiogenesis 15:71–85. doi:10.1007/s10456-011-9244-y
15. Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C, Di Carlo V, Allavena P, Piemonti L (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63:7451–7461
16. Loberg RD, Day LL, Harwood J, Ying C, St. John LN, Giles R, Neeley CK, Pienta KJ (2006) CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8:578–586. doi:10.1593/neo.06280
17. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, McCauley LK (2009) A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 69:1685–1692. doi:10.1158/0008-5472.CAN-08-2164
18. Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E, Koelbl H (2004) Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumor Biol 25:14–17. doi:10.1159/000077718
19. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67:9417–9424. doi:10.1158/0008-5472.CAN-07-1286
20. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, Wainstok R (2007) Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Investig Dermatol 127:2031–2041. doi:10.1038/sj.jid.5700827
21. Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ, Puchalski TA, Balkwill F, Berns B, Seetharam S, de Bono JS, Tolcher AW (2013) A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol 71:1041–1050. doi:10.1007/s00280-013-2099-8
22. Obmolova G, Teplyakov A, Malia TJ, Grygiel TLR, Sweet R, Snyder LA, Gilliland GL (2012) Structural basis for high selectivity of anti-CCL2 neutralizing antibody CNTO 888. Mol Immunol 51:227–233. doi:10.1016/j.molimm.2012.03.022
23. Rozel S, Galbán CJ, Nicolay K, Lee KC, Sud S, Neeley C, Snyder LA, Chenevert TL, Rehemtulla A, Ross BD, Pienta KJ (2009) Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem 107:58–64. doi:10.1002/jcb.22056
24. Moisan F, Francisco EB, Brozovic A, Duran GE, Wang YC, Seetharam S, Snyder LA, Doshi P, Sikic BI (2012) Enhancement of paclitaxel and carboplatin therapy by CCL2 blockade in ovarian cancers. Cancer Research 72 (8 suppl 1): abstr 817
25. Pienta KJ, Machiels J-P, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA, Takimoto C, Elsayed Y, Dawkins F, de Bono JS (2013) Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs 31:760–768. doi:10.1007/s10637-012-9869-8
26. Takimoto CH, Ng CM, Puchalski T (2011) Pharmacokinetics and pharmacodynamics. In: DeVita VTJ, Lawrence TS, Rosenberg SA (eds) DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology, 9th edn. Lippincott Williams & Wilkins, Philadelphia, pp 360–368
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026
28. Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, Egorin MJ (2008) Modulation of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin Cancer Res 14:3529–3535. doi:10.1158/1078-0432.CCR-07-4885
29. Fetterly GJ, Puchalski TA, Takimoto C, Mager DE, Seetharam S, McIntosh T, De Bono JS, Tolcher A, Davis HM, Zhou H (2010) Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data [ASCO abstract 3029]. J Clin Oncol 28:15S
30. Von Hoff DD, Nieves JA, Vocila LK, Weitman SD, Cvitkovic E (2007) The complete phase Ib clinical trial: a method to accelerate new agent development [ASCO abstract 2562]. J Clin Oncol 25:18S
31. The complete phase Ib trial design—an approach for getting to phase II faster. A Q&A with Daniel Von Hoff, M.D. Medelis website. http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design. Accessed 14 January 2013